黄芩苷通过蛋白酶体依赖性降解 DAPK1 阻断 PAR 死亡并保护免受缺血性脑卒中

《Neuropharmacology》:Proteasome-dependent degradation of DAPK1 by wogonoside blocks PARthanatos and protects against ischemic stroke

【字体: 大 中 小 】 时间:2026年10月12日 来源:Neuropharmacology 4.7

编辑推荐:

   •Wogonoside (WS) triggers proteasomal degradation of DAPK1 to block PARthanatos.•DAPK1 clearance halts JNK-AIF axis while preserving PARP1

  
  • •
    Wogonoside (WS) triggers proteasomal degradation of DAPK1 to block PARthanatos.
  • •
    DAPK1 clearance halts JNK-AIF axis while preserving PARP1-dependent DNA repair.
  • •
    DAPK1 degradation uncouples lethal cell death from genomic maintenance.
  • •
    WS attenuates ischemic brain infarction and preserves the neurovascular unit.
  • •
    Single-nucleus RNA-seq links Dapk1 to neuronal MAPK pro-death signaling.

Introduction

Ischemic stroke remains a leading cause of global mortality and disability (Collaborators, 2021). During cerebral ischemia, excessive oxidative stress and the overproduction of reactive oxygen species (ROS) act as early drivers of irreversible neuronal injury (Campbell et al., 2019; Liu et al., 2025). Accumulating evidence indicates that ROS-induced DNA damage triggers PARthanatos, a PARP1-dependent, caspase-independent form of programmed cell death that serves as the principal executioner of ischemic neuronal demise (Andrabi et al., 2006). Pathological ROS directly cause DNA strand breaks, which provoke PARP1 hyperactivation. This hyperactivation depletes cellular nicotinamide adenine dinucleotide (NAD+) and ATP reserves, precipitating a lethal bioenergetic crisis (Fatokun et al., 2014; Wu et al., 2025). Concurrently, the accumulation of free poly (ADP-ribose) (PAR) polymers induces mitochondrial depolarization and the nuclear translocation of apoptosis-inducing factor (AIF), which then associates with the PAAN (PAR-activated AIF-associated nuclease)/MIF nuclease complex to execute large-scale terminal DNA fragmentation (Huang et al., 2022; Mace et al., 2026).
Given the central role of oxidative stress in driving PARthanatos, pharmacological interception of this lethal cascade has been actively pursued. Direct catalytic inhibition of PARP1, using clinically approved agents such as olaparib or our recently identified natural quassinoid bruceine E (Wei et al., 2026), effectively blocks PARthanatos. Yet this approach presents a fundamental therapeutic paradox. Basal PARP1 activity is indispensable for recruiting DNA repair proteins, including XRCC1 and DNA ligase III, to resolve single-strand breaks through base excision repair (Gibson and Kraus, 2012). Consequently, indiscriminate PARP1 inhibition compromises genomic stability and may paradoxically exacerbate ROS-induced DNA lesions (Ray Chaudhuri and Nussenzweig, 2017). This fundamental limitation has motivated the search for downstream intervention nodes that would permit selective blockade of PARthanatos without impairing physiological DNA repair.
Within the ischemic penumbra, the c-Jun N-terminal kinase (JNK) pathway acts as a critical pro-death node exquisitely sensitive to oxidative stress (Hu et al., 2026). Upstream of JNK, death-associated protein kinase 1 (DAPK1), a calcium/calmodulin-regulated serine/threonine kinase extensively characterized in excitotoxicity (Tu et al., 2010), integrates multiple death stimuli, including ROS and DNA damage, to propagate lethal signaling (Zhang et al., 2025a). Notably, DAPK1 activates JNK through the GADD45a/MDM2 axis, linking oxidative stress sensing to mitochondrial dysfunction, ROS overproduction, and caspase-independent cell death. Whether DAPK1 functions as a kinase relay coupling PARP1 hyperactivation to the JNK–mitochondrial depolarization–AIF axis in PARthanatos, however, has remained unknown. Elucidating this position is of considerable importance, as it may reveal a druggable node entirely separable from PARP1-dependent DNA maintenance.
Through high-throughput phenotypic screening of a customized NMPA-approved library against an N-methyl-N′-nitro-N-nitrosoguanidine (MNNG)-induced PARthanatos model (Tang et al., 2019), we identified wogonoside (WS), a natural flavonoid glycoside derived from Scutellaria baicalensis (Pan et al., 2021; Zhang et al., 2025b), as a potent anti-PARthanatos lead compound with favorable preliminary tolerability. In this study, we employed a phenotype-to-target deconvolution strategy and identified DAPK1 as the direct molecular target of WS (Wang et al., 2017). Using integrated biophysical assays (Molina et al., 2013), 100-ns all-atom molecular dynamics simulations, and CRISPR/Cas9 genetic ablation (Le Cong et al., 2013), we demonstrate that WS acts as a ligand-induced degrader (KD = 6.07 μM) that triggers the proteasome-dependent clearance of DAPK1. This targeted degradation dismantles the JNK–mitochondrial depolarization–AIF execution axis while leaving PARP1 catalytic activity and genomic DNA repair fully intact. In a mouse permanent distal middle cerebral artery occlusion (pdMCAO) model, a single dose of WS reduced infarct volume by approximately 50%, rescued neurons, suppressed microglial activation, and preserved microvascular integrity (Iadecola, 2017; Iadecola and Anrather, 2011). Single-nucleus RNA sequencing revealed Dapk1 enrichment in activated microglia and co-variation with neuronal MAPK activity, suggesting a potential dual-compartment mechanism of protection. Collectively, these results identify proteasome-dependent DAPK1 degradation as a mechanistically distinct antioxidant strategy for halting ROS-driven PARthanatos in acute ischemic stroke.

Section snippets

Materials

All antibodies used in this study, including their sources, catalog numbers, and dilutions, are listed in Supplementary Table 1. All chemical compounds and reagents, including their sources and catalog numbers, are listed in Supplementary Table 2. Wogonoside (WS; purity ≥ 98%) was purchased from MedChemExpress (MCE, Shanghai, China) and dissolved in DMSO (cell culture grade) to prepare stock solutions, which were stored at ?20°C. The final DMSO concentration in all cell culture experiments did

Phenotypic screening identifies baicalein as a potent inhibitor of PARthanatos

To identify novel neuroprotective agents against ischemic stroke, we established a robust in vitro PARthanatos model by exposing HeLa cells to the DNA-alkylating agent MNNG (60 μM for 15 min) (Huang et al., 2022). Through a high-throughput phenotypic screening of a customized NMPA approved library (Tang et al., 2019), baicalein emerged as a preliminary hit capable of rescuing MNNG-induced cell death (Fig. 1A–C). Baicalein (5,6,7-trihydroxyflavone; C15H10O5; molecular structure shown in Fig. 1

Discussion

This study identifies death-associated protein kinase 1 (DAPK1) as an indispensable downstream executioner within the ROS-driven PARthanatos signaling cascade and demonstrates that wogonoside (WS)-induced proteasomal degradation of DAPK1 confers robust neuroprotection against ischemic stroke. Three findings are central to this conclusion. First, through a phenotype-to-target deconvolution strategy combining reverse pharmacophore mapping with a curated programmed cell death gene set, we

CRediT authorship contribution statement

Chun-Ze Zhai: Writing – original draft, Methodology, Investigation, Data curation. Yin Cao: Investigation. Yu-Xin Shen: Investigation. Yi-Zhe Wang: Investigation. Zhi-Peng Liu: Investigation. Fang Liu: Investigation. Jin-Liu Yu: Investigation. Xiu-Xiu Wang: Software, Methodology. Zhao-Huan Zhang: Writing – review & editing, Writing – original draft, Supervision, Project administration, Conceptualization. Xiao-Hui Xu: Writing – review & editing, Writing – original draft, Supervision, Project

Data availability statement

The single-nucleus RNA sequencing (snRNA-seq) dataset analyzed in this study has been deposited in the NCBI Gene Expression Omnibus (GEO) database and is publicly accessible under the accession number GSE250245 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE250245). All other raw data, uncropped Western blot images, and generated datasets supporting the conclusions of this article are available from the corresponding authors upon reasonable request.

Ethics statement

The animal experiments were approved by the Medical Ethics Committee of Wannan Medical College (approval number: WNMC-AWE-2025338). All experimental procedures were conducted in compliance with the ARRIVE guidelines (Kilkenny et al., 2010) and the relevant national and institutional regulations for the care and use of laboratory animals. The human-derived cell lines (HeLa and PC-9) used in this study are commercially available and were purchased from the Chinese Academy of Sciences Cell Bank.

Generative AI statement

The authors declare that generative AI and AI-assisted technologies were strictly not used in the writing of the manuscript text, data analysis, or the creation of experimental figures. However, AI-assisted tools were utilized to generate preliminary visual elements for the Graphical Abstract. Following the use of these tools, the authors extensively reviewed, manually adjusted, and scientifically curated the final image. The authors take full responsibility for the content and scientific

Funding

This work was supported by National Natural Science Foundation of China (no. 81671263); Scientific Research and Innovation Team, Education Department of Anhui Province, China (no. 2023AH010072).

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

None.
Chun-Ze Zhai|Yin Cao|Yu-Xin Shen|Yi-Zhe Wang|Zhi-Peng Liu|Fang Liu|Jin-Liu Yu|Xiu-Xiu Wang|Zhao-Huan Zhang|Xiao-Hui Xu
相关新闻
生物通微信公众号
微信
新浪微博
  • 搜索
  • 国际
  • 国内
  • 人物
  • 产业
  • 热点
  • 科普

热点排行

    今日动态 | 人才市场 | 新技术专栏 | 中国科学人 | 云展台 | BioHot | 云讲堂直播 | 会展中心 | 特价专栏 | 技术快讯 | 免费试用

    版权所有 生物通

    Copyright© eBiotrade.com, All Rights Reserved

    联系信箱:

    粤ICP备09063491号